Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma
Transcenta Holding Limited (HKG: 6628) announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) has...
HKG: 6628
Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026
Transcenta Holding Limited (HKG: 6628) announced that its joint venture, Inhibrx Biosciences, Inc. (NASDAQ: INBX),...
Transcenta’s LIV-1 ADCs Show Promising Results in Pre-Clinical Breast Cancer Study
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) announced updated results from a pre-clinical study...
Transcenta’s Osemitamab Combo Therapy Shows Promising Results in G/GEJ Cancer Treatment at ESMO 2024
Transcenta Holdings Ltd (HKG: 6628), a leading biopharmaceutical company, has announced updated positive results from...
Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...
Transcenta Secures FDA Approval for Phase III Trial of Osemitamab
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...
Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...
Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC/GEJ Cancer Study
Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data...
Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study
Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
Transcenta’s TST004 Receives FDA IND Clearance for IgAN Treatment
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received Investigational New Drug...
Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance
China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...
Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...